



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Joachim BUENGER et al.

Serial No.: 10/620,812

Group Art Unit: 1616

Filed: July 17, 2003

Examiner: Marina Lamm

For: ECTOIN OR ECTION DERIVATIVES AND SURFACTANTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☐ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☒ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
 - ☐ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
- ☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- ☐ a final action under 37 C.F.R. § 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
 - ☐ OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an international search report dated _____.
- ☐ Not required by 37 CFR § 1.98.
- ☒ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

☐ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

☐ Translation of other relevant information on foreign search report

[insert necessary translation here]

Other Information


Payment of Fees Due (If Any):

☐ A check for \$_____ covering the fee identified above is attached.

☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2206-P01

Date: February 6, 2005

CH:at

K:\Merck\Merck 2000 - 2999\2206P1\Information Disclosure Statement.doc



Please use a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/620,812
Filing Date	July 17, 2003
First Named Inventor	Joachim BUENGER et al.
Group Art Unit	1616
Examiner Name	Marina LAMM
Attorney Docket Number	MERCK-2206-P01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	2,649,397		Ballard	08-18-1953
	2	5,047,409		Di Schiena et al.	09-10-1991
	3	5,403,845		Dunbar et al.	04-04-1995
	4	4,346,105		Sallmann et al.	08-24-1982
	5	5,204,099		Barbier et al.	04-20-1993
	6	5,738,858		A. Burger	04-14-1998
	7	5,827,508		Tanner et al.	10-1998
	8	6,403,112		Motitschke et al.	06-11-2002
	9	5,789,414		Lapidot et al.	08-04-1998
	10	5,972,718		Moghaddam et al.	10-26-1999
	11	6,267,973		Motitschke et al.	07-31-2001
	12	6,551,971		Cobbley et al.	04-22-2003
	13	6,638,543		Kang et al.	10-28-2003
	14	6,153,176		Kaleta et al.	11-28-2000
	15	6,060,071		Motitschke et al.	05-09-2000
	16	4,529,587		Green et al.	07-16-1985
	17	6,057,282		Desai et al.	05-02-2000
	18	5,780,042		Gers-Barlag et al.	07-14-1998
	19	2003/0157040		Bunger et al.	08-21-2003
	20	6,602,514		Bunger et al.	08-05-2003
	21	2003/0114358		Galinski et al.	06-19-2003
	22	2004/0043940		Bunger et al.	03-04-2004
	23	08/355,275			
	24	08/746,253			
	25	09/834,976			
	26	08/953,988			
	27	09/425,285			
	28	09/744,766			
	29	10/355,149			
	30	09/744,945			
	31	10/620,812			
	32	09/744,767			
	33	10/239,394			
	34	10/239,073			
	35	10/363,469			
	36	10/363,789			

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/620,812		
		Filing Date	July 17, 2003		
		First Named Inventor	Joachim BUENGER et al.		
		Group Art Unit	1616		
		Examiner Name	Marina LAMM		
Sheet	3	of	3	Attorney Docket Number	MERCK-2206-P01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	75	Galinski et al., "1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic Acid," <i>Eur. J. Biochem.</i> 149:135-39 (1985).	
	76	Idson, B., "Dry Skin Moisturizing and Emolliency," <i>Cosmetics & Toiletries</i> 107:69-78 (1992)	
	77	Severin et al., "The Predominant Role of Recently Discovered Tetrahydropyrimidines For The Osmoadaptation of Halophilic Eubacteria," <i>Journal of General Microbiology</i> 138:1629-38 (1992).	
	78	J. Bunge : PARfumerie und kosmetik, vol. 79, no. 11, november 1998 pp. 32-35	
	79	KREZEL, I., "Antitumor activity of new derivatives of 1,3-diazaheterocycles," <i>Pharmazie</i> , vol. 53, no. 9, pp. 614-617, 1998.	
	60	ADAMS J.L. et al., "cis-4-Carboxy-6-(mercaptomethyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one, a potent inhibitor of mammalian dihydroorotase," <i>J. Med. Chem.</i> , vol. 31, no. 7, pp. 1355-1359, 1988.	
	61	DOI, MASAKO ET AL., "Cosmetic compositions containing plant extracts having moisture-retaining effects," Ichimaru Pharcos Inc., Japan, Japanese patent no. 2000053557, abstract.	
	62	SODERLING, EVA ET AL., "Betaine-containing toothpaste relieves subjective symptoms of dry mouth," Sandinavian University Press, 1998, pages 65-69, vol. 56, vol. 2.	
	63	RonaCare™ The Cell Protection Factor, Merck KgaA, Darmstadt, Germany, Ingredients for Cosmetics.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S.



	37	5,665,366		A. Rawlings et al.	09-09-1997
--	----	-----------	--	--------------------	------------

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	38	JP	2104577			1990		8
	39	JP	3086867			11-01-91		8
	40	JP	3031265			12-02-91		8
	41	WO	94/15923			07-21-94		
	42	EP	0 553 884			08-04-93		9
	43	EP	0 888 542			09-14-83		10
	44	DE	2 154 948			05-10-73		11
	45	DE	2 132 079			01-11-73		8
	46	WO	9,617,590			06-1996		12
	47	WO	98 13020		Unilever PLC	04-02-1998		13
	48	EP	0 275 719		Charles of The Ritz Group LTD	07-27-1988		14
	49	DE	4244580		Galinski et al.	07-1994		
	50	EP	0 671 161		Motitschke et al.	09-1995		15
	51	DE	4342560			06-22-1995		8
	52	DE	2746650			04-26-1979		16
	53	DE	2614723			04-26-1979		56
	54	GB	2114886			09-11-1983		
	55	EP	647469			04-12-1995		17
	56	DE	19933466			01-13-2000		
	57	DE	19933463			01-13-2000		
	58	DE	19933464			01-13-2000		
	59	DE	19933461			01-13-2000		
	60	DE	19933460			01-13-2000		
	61	WO	94 04128			03-03-1994		18
	62	DE	19834816			02-03-2000		19
	63	DE	199 11 775			02-03-2000		20
	64	DE	198 34 818			02-03-2000		
	65	EP	0915167			05-12-1999		
	66	WO	0007558			02-17-2000		19
	67	JP	9143167			06-03-1997		
	68	WO	0158446			08-16-2001		21
	69	WO	0172263			10-04-2001		22
	70	DE	10006578			08-23-2001		
	71	WO	0076528			12-21-2000		
	72	GB	1513659			06-07-1978		
	73	WO	0207522					
	74	WO	0302146					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.